188 related articles for article (PubMed ID: 28847527)
41. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
42. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
43. [The impact of ascorbic acid on the concentrations of antioxidative vitamins in the plasma of patients with non-small cell lung cancer undergoing first-line chemotherapy].
Tokarski S; Rutkowski M; Godala M; Mejer A; Kowalski J
Pol Merkur Lekarski; 2013 Sep; 35(207):136-40. PubMed ID: 24224449
[TBL] [Abstract][Full Text] [Related]
44. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
45. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
[TBL] [Abstract][Full Text] [Related]
46. Relationship between Energy Dosage and Apoptotic Cell Death by Modulated Electro-Hyperthermia.
Kao PH; Chen CH; Tsang YW; Lin CS; Chiang HC; Huang CC; Chi MS; Yang KL; Li WT; Kao SJ; Minnaar CA; Chi KH; Wang YS
Sci Rep; 2020 Jun; 10(1):8936. PubMed ID: 32488092
[TBL] [Abstract][Full Text] [Related]
47. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
Ni J; Liu DY; Hu B; Li C; Jiang J; Wang HP; Zhang L
Cancer; 2015 Sep; 121 Suppl 17():3146-56. PubMed ID: 26331821
[TBL] [Abstract][Full Text] [Related]
48. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
49. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V
Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732
[TBL] [Abstract][Full Text] [Related]
50. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
51. Modulated electro-hyperthermia enhances dendritic cell therapy through an abscopal effect in mice.
Qin W; Akutsu Y; Andocs G; Suganami A; Hu X; Yusup G; Komatsu-Akimoto A; Hoshino I; Hanari N; Mori M; Isozaki Y; Akanuma N; Tamura Y; Matsubara H
Oncol Rep; 2014 Dec; 32(6):2373-9. PubMed ID: 25242303
[TBL] [Abstract][Full Text] [Related]
52. Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models.
Krenacs T; Meggyeshazi N; Forika G; Kiss E; Hamar P; Szekely T; Vancsik T
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872532
[TBL] [Abstract][Full Text] [Related]
53. Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer.
Yoo HJ; Lim MC; Seo SS; Kang S; Joo J; Park SY
Jpn J Clin Oncol; 2019 Sep; 49(9):832-838. PubMed ID: 31070763
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study.
Liu J; Lin HS; Hou W; Hua BJ; Zhang PT; Li J; Wang SY; Xie Y; Zhang Y; Xie GR; Zhang MY; Shi WG; Guan NB; Guan TY; Li CH; Lu LY; Zhang Y; Li DR; Liu H
Chin J Integr Med; 2017 Oct; 23(10):733-739. PubMed ID: 27796823
[TBL] [Abstract][Full Text] [Related]
55. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
56. [A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].
Tredaniel J; Mornex F; Barillot I; Diaz O; Hennequin C; Le Pechoux C; Lavole A; Giraud P; Souquet PJ; Teixeira L; Vaylet F; Zalcman G; Baudrin L; Morin F; Milleron B
Rev Mal Respir; 2011 Jan; 28(1):51-7. PubMed ID: 21277474
[TBL] [Abstract][Full Text] [Related]
57. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
[TBL] [Abstract][Full Text] [Related]
58. Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients.
Fiorentini G; Sarti D; Ranieri G; Gadaleta CD; Fiorentini C; Milandri C; Mambrini A; Guadagni S
World J Clin Oncol; 2021 Nov; 12(11):1064-1071. PubMed ID: 34909400
[TBL] [Abstract][Full Text] [Related]
59. Modulated Electrohyperthermia: A New Hope for Cancer Patients.
Alshaibi HF; Al-Shehri B; Hassan B; Al-Zahrani R; Assiss T
Biomed Res Int; 2020; 2020():8814878. PubMed ID: 33274226
[TBL] [Abstract][Full Text] [Related]
60. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
